NASDAQ:JAZZ

Jazz Pharmaceuticals Stock News

etoro logo Buy JAZZ
*Your capital is at risk
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
The rollercoaster ride of the cannabis market has left many in the investing world dazed and confused. The sector's volatility is marked by winds of optimism followed by spells of disappointment.
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
Unlock your portfolio value with high earnings yield value stocks like URBN, ADNT, OVV, JAZZ and RNR that will boost your returns.
Meeting presentations underscore the increased need for awareness around the cardiovascular and cardiometabolic comorbidities and modifiable risk factors associated with sleep disorders Fourteen abstr
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down
Investors looking for stocks in the Medical - Drugs sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Zoetis (ZTS). But which of these two stocks presents investors with the better v
Cannabis stocks are undoubtedly a booming opportunity. Many investors consider this sector as a great opportunity to invest and compare it with the artificial intelligence and robotics sector.
The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.
The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on.
There's a reason people are looking for cannabis stocks to buy now. It is increasingly likely that marijuana will be rescheduled from a Schedule I controlled substance to a Schedule III controlled sub
DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
The global pharmaceutical cannabis market is poised for significant growth, projected to swell by 23% by 2027, mostly from one company but with other contenders battling to enter the market. In 2023,
Jazz Pharmaceuticals and Innovative Industrial Properties have been standouts in the cannabis industry. Both companies have been able to sidestep issues that plague their peers in the industry.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE